Study to Assess Efficacy and Safety of XC221 200 mg in the Treatment of Influenza or Other ARVI

Influenza Clinical Trial

Official title:

Double-blind Randomized Placebo-controlled Comparative Multicenter Study to Assess the Safety, Tolerability and Efficacy of XC221 in a Dose of 200mg Per Day in Patients With Uncomplicated Influenza or Other ARVI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03830905
• Other study ID #: ARI-XC221-03
• Status: Completed
• Phase: Phase 2
• Start date: January 31, 2019
• Est. completion date: July 3, 2019

Study information

• Verified date: November 2020
• Source: PHARMENTERPRISES LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The innovative drug XC221 is planned for use in treatment of acute respiratory viral infections in a double-blind, randomized, placebo-controlled, comparative multicenter study assessing the safety, tolerability and efficacy of XC221 at a dose of 200 mg per day in patients with uncomplicated influenza or other acute respiratory viral infections during the 3-days treatment.

Description:

A double-blind, randomized, placebo-controlled, comparative multicenter study in two groups. A total of 120 patients with uncomplicated influenza or other acute respiratory viral infections are planned to be randomized. Patients will be randomized into 2 groups: 60 patients in the treatment group 200 mg XC221 and 60 patients in the placebo group. The purpose of the clinical trial is to assess the safety, tolerability and efficacy of the drug XC21 in treatment of influenza or other acute respiratory viral infections. The primary objective is to demonstrate the difference between the groups in the time of the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale. The study will consist of the following periods: screening (duration not more than 36 hours from the moment of the first symptoms of the disease), treatment period (3 days), follow-up period (11 ± 1 days after completion of treatment with the study drug/placebo). The duration of participation in the study for each patient is no more than 16 days and 12 hours.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: July 3, 2019
• Est. primary completion date: July 3, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Both sexes aged 18 years and older.

2. Clinically diagnosed influenza or ARVI mild or moderate severity.

3. Patient's body temperature =37.5º? and at least 1 symptom from Modified Jackson Scale estimated more than 2 points.

4. Uncomplicated course of influenza or ARVI based on clinical estimations.

5. The first 36 hours from the beginning of symptoms of influenza or ARVI.

6. Women of reproductive age (who are not in menopause and who have not undergone surgical sterilization) and men who have sexual activity should use a reliable method of contraception (acceptable methods of contraception in this study are: intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, a double barrier method (condom and diaphragm with spermicide) throughout the study period.

7. Compliance with the treatment regimen, visits and laboratory examinations provided by the protocol.

8. Signed Informed Consent Form.

Exclusion Criteria:

1. Complications of influenza or ARVI (including the presence / development of bacterial infection).

2. The need for inpatient treatment of influenza and ARVI.

3. Hypersensitivity to excipients of the drug XC221 or placebo.

4. Antiviral medications 7 days prior to screening (antiviral agents, interferons and interferon inducers, drugs that have immunomodulating action) or anti-infective agents of systemic or local action.

5. Severe infection with signs of cardiovascular insufficiency development and other manifestations of infectious-toxic shock, as well as with the presence of neuroinfection syndrome (encephalic and meningoencephalic reactions, polyradiculoneuritis, neuritis).

6. Signs of of viral pneumonia symptoms (the presence of two or more of the following symptoms): dyspnea, chest pain when coughing, systemic cyanosis, dullness of percussion sound with a symmetrical evaluation of the upper and lower sections of the lungs).

7. Infectious diseases during the last week before including into the study.

8. Bronchial asthma, COPD, pulmonary emphysema in history.

9. History of increased convulsive activity.

10. Severe, decompensated or unstable somatic diseases (any diseases or conditions that are life-threatening or may worsen the patient's prognosis, and make him/her ineligible for the clinical study).

11. History of oncological diseases, HIV, tuberculosis.

12. Drug or alcohol abuse.

13. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

14. Participation in any other clinical trial in the last 90 days.

15. Pregnancy or lactation.

16. Military or prison populations.

17. Impossibility or inability to comply with the study procedures.

18. A member of the investigator's family or other person interested in the results of the study.

19. Deviations from laboratory standards, which prevent the inclusion of the patient in the study according to the Investigator.

20. A history of kidney failure.

Related Conditions & MeSH terms

• Acute Respiratory Viral Infections
• Influenza
• Influenza, Human
• Virus Diseases

Intervention

Drug:
• XC221
Participants will receive 200 mg XC221 once a day during 3 days
• Placebo
Participants will receive Placebo once a day during 3 days

Locations

Country	Name	City	State
Russian Federation	Federal State Budgetary Institution of Health "Northern Medical Clinical Center named after NA Semashko of the Federal Medical and Biological Agency"	Arkhangelsk
Russian Federation	Regional State Budgetary Institution of Health "Belgorod Regional Clinical Hospital of St. Joasaph"	Belgorod
Russian Federation	City Clinical Hospital ?9	Izhevsk
Russian Federation	Kuban State Medical University	Krasnodar
Russian Federation	State budget institution of health care of the Moscow region "Krasnogorsk city hospital number 1"	Krasnogorsk
Russian Federation	Non-governmental Healthcare Institution "N.A.Semashko Road Clinical Hospital at the Lyublino station of the open joint-stock company "Russian Railways"	Moscow
Russian Federation	Federal State Budgetary Educational Institution of Higher Education "Ryazan State Medical University named after Academician I.P. Pavlova" of the Ministry of Health of the Russian Federation	Ryazan
Russian Federation	Ryazan State Medical University n.a. Pavlov	Ryazan'
Russian Federation	City Clinical Hospital ?40 of Kurortny District	Saint Petersburg
Russian Federation	Research Institute of Influenza	Saint Petersburg
Russian Federation	The Center for Prevention and Fight about AIDS and Infectious Diseases	Saint Petersburg
Russian Federation	The Consulting and Diagnostic Center with out-patient help of the Administration of the President of the Russian Federation	Saint Petersburg
Russian Federation	LLC "Astarta"	St. Petersburg
Russian Federation	LLC "Aurora Medi"	St. Petersburg
Russian Federation	Federal State Budgetary Educational Institution of Higher Education "Yaroslavl State Medical University" of the Ministry of Health of the Russian Federation	Yaroslavl
Russian Federation	State Budgetary Healthcare Institution (SBHI) of Yaroslavl region	Yaroslavl

Sponsors (2)

Lead Sponsor	Collaborator
PHARMENTERPRISES LLC	RSV Therapeutics LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The average concentration of MxA protein in the blood at Visit 1, Visit 4 and at Visit 6.		From Day 1 up to Day 6
Other	Changes in the concentration of MxA protein in the blood at Visit 4 and at Visit 6 compared to Visit 1.		From Day 1 up to Day 6
Other	The average concentration of C-reactive protein in the blood at Visit 1, Visit 4 and Visit 6.		From Day 1 up to Day 6
Other	Changes in the concentration of C-reactive protein in the blood at Visit 4 and Visit 6 compared to Visit 1.		From Day 1 up to Day 6
Other	The average concentration of cytokines at Visit 1, Visit 4 and at Visit 6.	The average concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-a, Gro-ß, I-309, IFN- ?, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1a, MIP-1d, MIP-3a, MIP-3ß, MPIF-1, SCYB16, SDF-1a + ß, TARC, TECK, TNF-a in blood at Visit 1, Visit 4 and at Visit 6.	From Day 1 up to Day 6
Other	The percentage change in the concentration of cytokines at Visit 4 and at Visit 6 compared with Visit 1.	The percentage change in the concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-a, Gro-ß, I-309, IFN -?, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3 , MCP-4, MDC, MIF, MIG, MIP-1a, MIP-1d, MIP-3a, MIP-3ß, MPIF-1, SCYB16, SDF-1a + ß, TARC, TECK, TNF-a in blood at Visit 4 and Visit 6 compared with Visit 1.	From Day 1 up to Day 6
Other	Correlation between the concentration of cytokines/chemokines and the assessment of the Modified Jackson scale for measuring respiratory symptoms (in dynamics).	Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Other	The average concentration of cytokines in a smear from the mucosa of the nasopharynx and oropharyngeal at Visit 1, Visit 4 and Visit 6	The average concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-a, Gro-ß, I-309, IFN- ?, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1a, MIP-1d, MIP-3a, MIP-3ß, MPIF-1, SCYB16, SDF-1a + ß, TARC, TECK, TNF-a in a smear from the mucosa of the nasopharynx and oropharyngeal at Visit 1, Visit 4 and Visit 6.	From Day 1 up to Day 6
Other	The percentage change in the concentration of cytokines in a smear from the mucous membrane of the nasopharynx and oropharynx of patients on Visit 4 and on Visit 6 compared to Visit 1.	The percentage change in the concentration of 6Ckine, BCA-1, CTACK, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, Fractalkine, GCP-2, GM-CSF, Gro-a, Gro-ß, I-309, IFN- ?, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10, IL-16, IP-10, I-TAC, MCP-1, MCP-2, MCP-3, MCP-4, MDC, MIF, MIG, MIP-1a, MIP-1d, MIP-3a, MIP-3ß, MPIF-1, SCYB16, SDF-1a + ß, TARC, TECK, TNF-a in a smear from the mucous membrane of the nasopharynx and oropharynx of patients on Visit 4 and on Visit 6 compared to Visit 1.	From Day 1 up to Day 6
Primary	Time to sustained improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms.	The time before the onset of sustained improvement in clinical symptoms according to the Modified Jackson Scale (no more than 1 point for each symptom), measured in hours from the moment of the first dose of the drug.; Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Secondary	The time before the onset of persistent improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms (0 points).	The time of the first assessment of 3 consecutive ratings on the Modified Jackson Scale, in which all the clinical symptoms were 0 points.; Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Secondary	The time before the onset of persistent improvement in clinical symptoms according to the Modified Jackson Scale for measuring respiratory symptoms.	Total score of no more than 3 points, when there is no more than 1 point for each symptom, measured in hours from the moment of taking the first dose of the drug.; Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Secondary	Time to normalization of body temperature.	Measured in hours. Normalization means the establishment of body temperature below 37° C without a rise above these values in the subsequent observation period.	From the moment of the first dose up to Day 14
Secondary	The average score according to the Modified Jackson Scale for measuring respiratory symptoms at the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th days.	The average score according to the Modified Jackson Scale on the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 8th days.; Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Secondary	The proportion of patients with a sum of not more than 3 points according to the Modified Jackson Scale for measuring respiratory symptoms at the 1st, 2nd, 3rd, 4th, 5th, 6th , The 7th, 8th days	Score for each symptom should be no higher than 1 point at the 1st, 2nd, 3rd, 4th, 5th, 6th , The 7th, 8th days from the moment of the start of treatment.; Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Secondary	The proportion of patients with the normalization of body temperature on the first - the 14th days from the start of treatment;		From the moment of the first dose up to Day 14
Secondary	Time to disappearance (0 points) of each of the symptoms according to the Modified Jackson Scale for measuring respiratory symptoms.	Symptom (sneezing, rhinorrhea, nasal congestion, cough, fever, malaise, chills, headache, myalgia, sore throat, tickling, hoarseness) manifested at the level of 2 or 3 points at the first assessment at Visit 0 (Day 0).; Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Secondary	The proportion of patients with 0 points score for each of the symptoms according to the Modified Jackson Scale for measuring respiratory symptoms.	Modified Jackson Scale (sneezing, rhinorrhea, nasal congestion, cough, fever, malaise, chills, headache, myalgia, sore throat, tickling, hoarseness) at the 2nd, 3rd 2nd, 4th, 5th, 6th, 7th and 8th days from the moment of the start of treatment in a population of patients with the corresponding symptom shown at the level of 2 or 3 points at Visit 0 (Day 0).; Modified Jackson Scale measures individuals' subjective ratings the severity of 12 respiratory symptoms. Ranges for each symptom: 0 points (no symptoms) - 3 points (the most severe). Total score (ranges from 0 to 32 points) is a sum of the point for each symptom.	From the moment of the first dose up to Day 14
Secondary	The proportion of patients with a detected viral pathogen	The proportion of patients with a detected viral pathogen at Visit 0, Visit 4 and Visit 6.	From the moment of the first dose up to Day 14
Secondary	The proportion of patients with a detected viral pathogen at Visit 4 and Visit 6 compared with the initial proportion of such patients in the XC221.		From the moment of the first dose up to Day 14
Secondary	The frequency of adverse events (AEs) and serious adverse events (SAEs) in the XC221 treatment group and in the placebo group.		From the moment of the first dose up to Day 14